PDS Biotechnology (PDSB) Competitors $0.93 -0.02 (-2.04%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$0.96 +0.03 (+3.10%) As of 10/17/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PDSB vs. SXTC, MIST, MCRB, CGEN, ELDN, CCCC, THTX, PEPG, MOLN, and NKTXShould you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include China SXT Pharmaceuticals (SXTC), Milestone Pharmaceuticals (MIST), Seres Therapeutics (MCRB), Compugen (CGEN), Eledon Pharmaceuticals (ELDN), C4 Therapeutics (CCCC), Theratechnologies (THTX), PepGen (PEPG), Molecular Partners (MOLN), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry. PDS Biotechnology vs. Its Competitors China SXT Pharmaceuticals Milestone Pharmaceuticals Seres Therapeutics Compugen Eledon Pharmaceuticals C4 Therapeutics Theratechnologies PepGen Molecular Partners Nkarta China SXT Pharmaceuticals (NASDAQ:SXTC) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk. Which has more volatility & risk, SXTC or PDSB? China SXT Pharmaceuticals has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Do institutionals and insiders hold more shares of SXTC or PDSB? 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Comparatively, 9.2% of PDS Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate SXTC or PDSB? PDS Biotechnology has a consensus price target of $10.00, suggesting a potential upside of 979.56%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe PDS Biotechnology is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media refer more to SXTC or PDSB? In the previous week, China SXT Pharmaceuticals had 1 more articles in the media than PDS Biotechnology. MarketBeat recorded 1 mentions for China SXT Pharmaceuticals and 0 mentions for PDS Biotechnology. China SXT Pharmaceuticals' average media sentiment score of 1.00 beat PDS Biotechnology's score of 0.00 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment China SXT Pharmaceuticals Positive PDS Biotechnology Neutral Is SXTC or PDSB more profitable? China SXT Pharmaceuticals' return on equity of 0.00% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets China SXT PharmaceuticalsN/A N/A N/A PDS Biotechnology N/A -184.56%-79.00% Which has better earnings & valuation, SXTC or PDSB? China SXT Pharmaceuticals has higher revenue and earnings than PDS Biotechnology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina SXT Pharmaceuticals$1.74M95.96-$3.30MN/AN/APDS BiotechnologyN/AN/A-$37.61M-$0.92-1.01 SummaryChina SXT Pharmaceuticals beats PDS Biotechnology on 7 of the 12 factors compared between the two stocks. Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PDSB vs. The Competition Export to ExcelMetricPDS BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.56M$3.44B$6.19B$10.55BDividend YieldN/A2.28%5.70%4.81%P/E Ratio-1.0123.0185.5427.13Price / SalesN/A486.53611.78133.04Price / CashN/A46.9237.1060.81Price / Book1.8210.4112.236.52Net Income-$37.61M-$52.77M$3.33B$276.93M7 Day Performance-2.22%2.31%1.17%1.93%1 Month Performance-11.78%12.59%6.85%2.19%1 Year Performance-71.50%11.18%58.93%34.62% PDS Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PDSBPDS Biotechnology1.2163 of 5 stars$0.93-2.0%$10.00+979.6%-71.5%$43.56MN/A-1.0120SXTCChina SXT Pharmaceuticals1.0778 of 5 stars$1.45-1.9%N/A-71.5%$171.49M$1.74M0.0090Positive NewsShort Interest ↓MISTMilestone Pharmaceuticals2.1545 of 5 stars$1.99flat$4.50+126.1%+30.2%$169.14M$1M-2.3730MCRBSeres Therapeutics2.3938 of 5 stars$19.23+0.6%$14.33-25.5%+11.6%$167.39M$126.32M-4.18330CGENCompugen1.6527 of 5 stars$2.24+21.1%$4.00+78.6%+9.6%$165.09M$27.86M-10.1870News CoverageGap UpHigh Trading VolumeELDNEledon Pharmaceuticals1.8091 of 5 stars$2.72-0.7%$10.00+267.6%+15.8%$164.08MN/A-2.3210News CoverageGap UpCCCCC4 Therapeutics3.5467 of 5 stars$2.11-6.2%$8.50+302.8%-62.7%$160.13M$35.58M-1.34150News CoverageTHTXTheratechnologiesN/A$3.42+0.9%N/A+157.1%$157.21M$84.38M-17.99140High Trading VolumePEPGPepGen3.0095 of 5 stars$4.55-3.6%$8.40+84.6%-45.3%$154.65MN/A-1.5430Short Interest ↑MOLNMolecular Partners1.4854 of 5 stars$3.87+1.7%$8.00+107.0%-22.1%$153.42M$5.65M-1.86180Analyst ForecastGap DownNKTXNkarta2.4538 of 5 stars$2.26+4.6%$13.50+497.3%-46.0%$153.41MN/A-1.53140 Related Companies and Tools Related Companies SXTC Competitors MIST Competitors MCRB Competitors CGEN Competitors ELDN Competitors CCCC Competitors THTX Competitors PEPG Competitors MOLN Competitors NKTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PDSB) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PDSB Stock Alerts